Clinical trial Recruiting at 1 site Observational Ages 6 to 12

Pain and sleep problems in children who survived cancer

Official title: The Co-Morbidity of Pain and Sleep Disturbances in Children Living Beyond Cancer: A Case-Control Study

Run by Vrije Universiteit Brussel · NCT07120646 · Data updated 2026-11-12

This study tests how pain and sleep disturbances relate in children who survived cancer compared with healthy peers.

Quick facts

Study typeObservational
Ages6 Years to 12 Years
SexAll
Enrollment76 (estimated)
SponsorVrije Universiteit Brussel
Academic / other
Drugs / interventionsimmunotherapy
Locations2 sites (Brussels, Brussels Capital and 1 other locations)
StatusRecruiting
StartedOctober 1, 2025
Main results expectedDecember 2026
Study endsDecember 2026
Registry record updatedSeptember 15, 2026
Trial IDNCT07120646 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children aged 6–12 who completed cancer treatment within the last 5 years and fluent in Dutch, with a healthy control group matched by age and sex.

Probably not a fit

Children with active cancer or significant cognitive/psychiatric conditions may not benefit from this observational study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational case-control study compares childhood cancer survivors aged 6–12 who are up to 5 years post-treatment with age- and sex-matched healthy controls. It uses questionnaires, actigraphy, and sleep diaries to assess pain and sleep patterns over time. The goal is to understand how pain and sleep interact and to identify potential targets for prevention and intervention. The study is conducted at Vrije Universiteit Brussel with support from Research Foundation Flanders. The lead site is in Brussels, Belgium, and Dutch, French, and English language tools are used for participation.

Why it matters

Potential benefit: Findings could inform better screening and early interventions for pain and sleep problems in CBC.

How similar studies have gone: Prior studies have shown meaningful associations between pain and sleep in pediatric populations, supporting the potential relevance of this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* CBC: 1) current age 6-12yo; 2) history of any cancer diagnosis; 3) ≤ 5y post- treatment completion; 4) ≥ 3 months since last cancer treatment (since pain and insomnia during treatment can be directly related to therapy and recover spontaneously); 5) fluent Dutch speaker and reader (age-dependent)
* Healthy controls (age- and sex-matched): 1) current age 6-12yo; 2) no history of cancer ; 3) fluent Dutch/French/English speaker and reader (age-dependent)
* Parents: 1) fluent Dutch/French/English speaker and reader

Exclusion Criteria:

* CBC: 1) receiving palliative therapy; 2) psychiatric disorder; 3) severe intellectual disability
* Healthy controls: 1) history of cancer; 2) psychiatric disorder; 3) severe intellectual disability

Where it's running

  • Vrije Universiteit Brussel
    Brussels, Brussels Capital, Belgium
    Recruiting
  • Vrije Universiteit Brussel
    Jette, Brussels Capital, Belgium
    Not yet recruiting

Study contacts

  • Principal investigator: Emma Rheel, PhD — Vrije Universiteit Brussel
  • Study coordinator: Emma Rheel, PhD
  • Email: emma.rheel@vub.be
  • Phone: +32496908353

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.